Stock Scorecard

Stock Summary for Aura Biosciences Inc (AURA) - $8.20 as of 12/20/2024 8:16:06 PM EST

Total Score

10 out of 30

Safety Score

23 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for AURA

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for AURA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for AURA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for AURA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for AURA (23 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 1
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0

Latest News for for AURA

Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference - Aura Biosciences ( NASDAQ:AURA ) 11/26/2024 1:00:00 PM
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema 11/7/2024 2:05:00 PM
Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease - Aura Biosciences ( NASDAQ:AURA ) 10/18/2024 1:16:00 PM
3 Small-Cap Stocks Ready to Deliver Significant Growth - Aura Biosciences ( NASDAQ:AURA ) , Franklin BSP Realty Trust ( NYSE:FBRT ) 10/15/2024 4:40:00 PM
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study 9/13/2024 1:30:00 PM
Aura Biosciences Touts Promising Data From Eye Cancer Candidate - Aura Biosciences ( NASDAQ:AURA ) 9/12/2024 3:40:00 PM
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma 9/12/2024 10:30:00 AM
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma - Aura Biosciences ( NASDAQ:AURA ) 9/12/2024 10:30:00 AM
Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer ( NMIBC ) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024 9/3/2024 8:05:00 PM
Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting 8/26/2024 8:05:00 PM

Financial Details for AURA

Company Overview
Ticker AURA
Company Name Aura Biosciences Inc
Country USA
Description N/A
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History
Last Day Price 8.20
Price 4 Years Ago 0.00
Last Day Price Updated 12/20/2024 8:16:06 PM EST
Last Day Volume 612,493
Average Daily Volume 219,024
52-Week High 12.38
52-Week Low 6.63
Last Price to 52 Week Low 23.68%

Valuation Measures
Trailing PE N/A
Industry PE 125.61
Sector PE 40.44
5-Year Average PE -4.38
Free Cash Flow Ratio 16.08
Industry Free Cash Flow Ratio 15.99
Sector Free Cash Flow Ratio 27.17
Current Ratio Most Recent Quarter 12.47
Total Cash Per Share 0.51
Book Value Per Share Most Recent Quarter 3.51
Price to Book Ratio 2.32
Industry Price to Book Ratio 5.62
Sector Price to Book Ratio 20.63
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 14.60
Sector Price to Sales Ratio Twelve Trailing Months 24.53
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 3

Share Statistics
Total Shares Outstanding 49,951,500
Market Capitalization 409,602,300
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -30.03%
Reported EPS 12 Trailing Months -1.73
Reported EPS Past Year -1.23
Reported EPS Prior Year -1.98
Net Income Twelve Trailing Months -83,216,000
Net Income Past Year -76,408,000
Net Income Prior Year -58,763,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 2,794.82%
Operating Margin Twelve Trailing Months 0.00

Balance Sheet
Total Cash Most Recent Quarter 25,407,000
Total Cash Past Year 41,063,000
Total Cash Prior Year 188,800,000
Net Cash Position Most Recent Quarter 25,407,000
Net Cash Position Past Year 41,063,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 49,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 225,848,000
Total Stockholder Equity Prior Year 195,583,000
Total Stockholder Equity Most Recent Quarter 174,668,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -74,511,000
Free Cash Flow Per Share Twelve Trailing Months -1.49
Free Cash Flow Past Year -64,556,000
Free Cash Flow Prior Year -55,695,000

Options
Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.32
MACD Signal -0.34
20-Day Bollinger Lower Band 6.91
20-Day Bollinger Middle Band 9.14
20-Day Bollinger Upper Band 11.38
Beta 0.33
RSI 40.87
50-Day SMA 8.45
150-Day SMA 11.30
200-Day SMA 0.00

System
Modified 12/20/2024 6:20:30 PM EST